Please assess the completion status of the following clinical trial:

Trial Title: Pretomanid in Adults With Hepatic Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion Criteria for Patients with Hepatic Impairment (Groups 1-3):~1. Subject is able to give voluntary written informed consent before any study related procedure is performed.~2. 18-70 years of age, inclusive.~3. Acceptable laboratory values\* obtained at screening (within 21 days prior to admission to the confinement/hospital unit) and either at or within 72 hours of admission to the confinement/hospital unit.~   \*Chemistry, complete blood count, AST, ALT, total bilirubin, alkaline phosphatase, albumin, and urinalysis deemed not clinically significant by the investigator.~4. Hepatic impairment classified as Child-Pugh class A (mild), B (moderate), or C (severe) criteria at screening for Groups 1, 2, or 3, respectively, and documented evidence of hepatic cirrhosis\*.~   \*by biopsy, nuclear scan, CT, MRI, ultrasound, or other clinically acceptable methods~5. If female, not of childbearing potential\* or agrees to avoid becoming pregnant by using acceptable contraception\*\* during the duration of the study.~   \*Non-childbearing potential is defined as being post-menopausal for at least 2 years, status after bilateral oophorectomy or status after hysterectomy.~  * Females of childbearing potential must agree to use two acceptable methods of contraceptives: bilateral tubal ligation; barrier method (condom) by the male partner (even if vasectomized); hormonal contraceptives; intrauterine contraceptive devices; diaphragm in combination with contraceptive jelly, cream, foam, or spermicide; and abstinence from sexual intercourse with men.~6. If subject is male and capable of reproduction, agrees to avoid fathering a child for three months after dosing by using an acceptable method of birth control\*.~   \*In addition to the use of a barrier method (condom) even if vasectomized, acceptable methods of birth control are restricted to a monogamous relationship with a woman who agrees to use acceptable contraception as outlined in inclusion criterion #5, and abstinence from sexual intercourse with women.~7. If the subject is female, a negative serum pregnancy test at screening and a negative urine pregnancy test at admission to the confinement/hospital unit.~8. Willingness to comply with all protocol requirements.~Inclusion Criteria for Non-Hepatically Impaired Controls (Group 4):~1. Subject is able to give voluntary written informed consent before any study related procedure is performed.~2. 18-70 years of age, inclusive.~3. Subject is a healthy volunteer as determined by no clinically significant findings from medical history, physical examination, vital signs, and 12-lead ECG as determined by the Site Investigator.~4. Acceptable laboratory values\* obtained at screening (within 21 days prior to admission to the confinement/hospital unit) and either at or within 72 hours of admission to the confinement/hospital unit.~   \*Chemistry, complete blood count, AST, ALT, total bilirubin, alkaline phosphatase, albumin, and urinalysis within the reference range for the test laboratory, unless deemed not clinically significant by the investigator.~5. If female, not of childbearing potential\* or agrees to avoid becoming pregnant by using acceptable contraception\*\* during the duration of the study.~   \*Non-childbearing potential is defined as being post-menopausal for at least 2 years, status after bilateral oophorectomy or status after hysterectomy.~   \*\*Females of childbearing potential must agree to use two acceptable methods of contraceptives: bilateral tubal ligation; barrier method (condom) by the male partner (even if vasectomized); hormonal contraceptives; intrauterine contraceptive devices; diaphragm in combination with contraceptive jelly, cream, foam, or spermicide; and abstinence from sexual intercourse with men.~6. If subject is male and capable of reproduction, agrees to avoid fathering a child for three months after dosing by using an acceptable method of birth control\*.~   \*In addition to the use of a barrier method (condom) even if vasectomized, acceptable methods of birth control are restricted to a monogamous relationship with a woman who agrees to use acceptable contraception as outlined in inclusion criterion #5, and abstinence from sexual intercourse with women.~7. If the subject is female, a negative serum pregnancy test at screening and a negative urine pregnancy test at admission to the confinement/hospital unit.~8. Willingness to comply with all protocol requirements.~Exclusion Criteria:~Exclusion Criteria for Patients with Hepatic Impairment (Groups 1-3):~1. Hypokalemia (\< 3.5mEq/L), severe hypomagnesemia (\< 1.1 mg/dL) or severe hypocalcemia (\< 7.5 mg/dL).~2. AST or ALT \> 10 times the upper limit of normal.~3. Creatinine clearance \< 60 ml/min.~4. Inability to swallow tablets.~5. Presence of any condition or finding\* which would jeopardize subject safety, impact study result validity, or diminish the subject's ability to undergo all study procedures and assessments\*\*.~   \*in the opinion of the site investigator~   \*\*e.g., inability to draw PK samples~6. History of fever or documented fever (oral temperature \> / = 100.4 degrees F or \> / = 38.0 degrees C) in the 48 hours prior to admission to the the confinement/hospital unit.~7. Currently breastfeeding.~8. History of chronic tobacco/nicotine use (\> 10 cigarettes per day for 3 months minimum prior to admission).~9. History of clinically significant allergy or severe side effects with nitroimidazoles (e.g., Metronidazole and related substances and azole antifungals or aromatase inhibitors).~10. Receipt of an investigational drug, vaccine or biologic in a clinical trial within 30 days prior to screening.~11. Use of any over the counter (OTC) medication\* within 7 days prior to admission to the confinement/hospital unit, unless\*\* the substance would not likely impact the validity of the study results.~    \*including vitamins and herbal supplements, cough and cold medications.~    \*\*in the opinion of the site investigator~12. Treatment with CYP450 enzyme altering drugs\* within 7 days prior to admission to the confinement/hospital unit, unless\*\* the substance would not likely impact the validity of the study results.~    * except hormonal contraceptives~      * in the opinion of the site investigator NOTE: See list of CYP450 enzyme altering drugs under the concomitant medications section.~13. A positive blood screen for HIV.~14. A positive alcohol breath test (or other suitable test for alcohol) or a urine screen test for drugs of abuse\* at screening and at admission to the confinement/hospital unit.~    \*Amphetamines, barbiturates, cocaine metabolites, marijuana, opiates, phencyclidine (PCP).~    NOTE: Results of the urine screen test can be ignored if in the opinion of the PI the results can be explained by the concomitant medications history.~15. Unwillingness to abstain from engaging in strenuous physical activity (e.g. running, bicycling, weightlifting, competitive sports) during the course of the study.~16. Consumption of grapefruit juice in the 48 hours before admission to the confinement/hospital unit, or the inability to abstain from these until completion of Day 12.~17. A QTcF interval \> 450 msec (males) or \> 450 msec (females) at screening (Visit 00A) or admission to the confinement/hospital unit (Visit 00B) or a history of prolonged QTc interval.~18. A family history\* of Long QT Syndrome, premature cardiac death\*\*, or sudden death without a preceding diagnosis of a condition\*\*\* that could be causative of sudden death.~    \*parents~    \*\*due to ischemic heart disease or sudden cardiac death before 55 years of age (men) or 65 years of age (women)~    \*\*\*such as known coronary artery disease, congestive heart failure, or terminal cancer~19. Any clinically significant ECG abnormality, in the opinion of the site investigator, at screening and at admission to the confinement/hospital unit.~20. Donation of \> 500 mL blood within the 30 days prior to admission to the confinement/hospital unit.~21. Plans to donate blood during the study or up to 14 days after dosing.~22. Persons with a transjugular intrahepatic portosystemic shunt.~Exclusion Criteria for Non-Hepatically Impaired Controls (Group 4):~1. Inability to swallow tablets.~2. Presence of any condition or finding\* which would jeopardize subject safety, impact study result validity, or diminish the subject's ability to undergo all study procedures and assessments\*\*.~   \*in the opinion of the site investigator~   \*\*e.g., inability to collect PK samples~3. History of fever or documented fever (oral temperature \> / = 100.4 degrees F or \> / = 38.0 degrees C) in the 48 hours prior to admission to the confinement/hospital unit.~4. Currently breastfeeding.~5. History of chronic tobacco/nicotine use (\> 10 cigarettes per day for 3 months minimum prior to admission to the confinement/hospital unit).~6. History of seizures (other than febrile seizures during childhood) or known or suspected CNS disorders that may predispose to seizures.~7. History of clinically significant allergy or severe side effects with nitroimidazoles (e.g., Metronidazole and related substances and azole antifungals or aromatase inhibitors).~8. Receipt of an investigational drug, vaccine or biologic in a clinical trial within 30 days prior to screening.~9. Use of any over the counter (OTC) medication\* within 7 days prior to admission to the confinement/hospital unit, unless\*\* the substance would not likely impact the validity of the study results.~   \*including vitamins and herbal supplements, antacids, cough and cold medications.~   \*\*in the opinion of the site investigator~10. Use of prescription medication except hormonal contraceptives within 30 days prior to admission to the confinement/hospital unit, unless\* the substance would not likely impact study result validity.~    \*in the opinion of the site investigator~11. Treatment with CYP450 enzyme altering drugs\* within 7 days prior to admission to the confinement/hospital unit, unless\*\* the substance would not likely impact the validity of the study results.~    \*except hormonal contraceptives~    \*\*in the opinion of the site investigator NOTE: See list of CYP450 enzyme altering drugs under the concomitant medications section.~12. A positive blood screen for HIV.~13. A positive blood screen for hepatitis B surface antigen (HBsAg), or hepatitis C antibody.~14. A positive alcohol breath test (or other suitable test for alcohol) or a urine screen test for drugs of abuse\* at screening and at admission to the confinement/hospital unit.~    \*Amphetamines, barbiturates, benzodiazepines, cocaine metabolites, marijuana, opiates, phencyclidine (PCP).~15. A history of alcohol abuse or dependence within the past 1 month prior to admission to the confinement/hospital unit.~16. Unwillingness to abstain from engaging in strenuous physical activity (e.g. running, bicycling, weightlifting, competitive sports) during the course of the study.~17. Consumption of grapefruit juice in the 48 hours before admission to the confinement/hospital unit, or the inability to abstain from these until completion of Day 12.~18. A QTcF interval \> 450 msec (males) or \> 450 msec (females) at screening (Visit 00A) or admission to the confinement/hospital unit (Visit 00B) or a history of prolonged QTc interval.~19. A family history\* of Long QT Syndrome, premature cardiac death\*\*, or sudden death without a preceding diagnosis of a condition\*\*\* that could be causative of sudden death.~    \*parents~    \*\*due to ischemic heart disease or sudden cardiac death before 55 years of age (men) or 65 years of age (women)~    \*\*\*such as known coronary artery disease, congestive heart failure, or terminal cancer~20. Any clinically significant ECG abnormality, in the opinion of the site investigator, at screening and at admission to the confinement/hospital unit.~21. Donation of \> 500 mL of blood within the 30 days prior to admission to the confinement/hospital unit.~22. Plans to donate blood during the study or up to 14 days after dosing.~23. Persons with a transjugular intrahepatic portosystemic shunt.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Child-Pugh A (Mild hepatic impairment) (Type: EXPERIMENTAL): 6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
- Child-Pugh B (Moderate hepatic impairment) (Type: EXPERIMENTAL): 6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
- Child-Pugh C (Severe hepatic impairment) (Type: EXPERIMENTAL): 6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
- Non-hepatically impaired controls (Type: EXPERIMENTAL): 18 matched Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy